Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma

Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T‐cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL.

[1]  M. Kashani-Sabet.  Treatment of Cutaneous T-Cell Lymphoma , 2004 .

[2]  M. Territo,et al.  Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma. , 2004, Clinical lymphoma.

[3]  A. Avilés,et al.  Gemcitabine and Cisplatin in Refractory Malignant Lymphoma , 2004, Oncology.

[4]  E. Knobler.  Current management strategies for cutaneous T-cell lymphoma. , 2004, Clinics in dermatology.

[5]  M. Erlanson,et al.  A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. , 2004, Blood.

[6]  A. Hauschild,et al.  Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T‐cell lymphoma , 2003, Cancer.

[7]  D. Koh,et al.  Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM‐P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[8]  G. Salles,et al.  Gemcitabine as a single agent in the treatment of relapsed or refractory low‐grade non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[9]  V. Diehl,et al.  Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Pileri,et al.  Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Döhner,et al.  Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  W. Hiddemann,et al.  Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Kurzrock,et al.  Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  S. Sallah,et al.  The role of 2‐chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia , 1999, British journal of haematology.

[16]  S. Pileri,et al.  Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  F. Aranha,et al.  Treatment of prolymphocytic leukemia with cladribine , 1998, Annals of Hematology.

[18]  H. Kerl,et al.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. , 1997, Blood.

[19]  F. Fox,et al.  The Potential Therapeutic Role of Interleukin‐12 in Cutaneous T‐Cell Lymphoma a , 1996, Annals of the New York Academy of Sciences.

[20]  K. Maclennan,et al.  The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[22]  L. Sobin,et al.  TNM classification of malignant tumors. A comparison between the new (1987) and the old editions , 1988, Cancer.

[23]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  R. Russell‐Jones.  World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. , 2003, Journal of the American Academy of Dermatology.

[26]  U. Wollina,et al.  Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. , 2000, Journal of the American Academy of Dermatology.

[27]  F. Gherlinzoni,et al.  Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. , 2000, Haematologica.